



Imported Malaria: Key Messages in an Era of Elimination.

Journal:	<i>Clinical Medicine</i>
Manuscript ID	CM-2018-0367
Manuscript Type:	CME article
Keywords:	Malaria, Imported infection, Malaria elimination

SCHOLARONE™
Manuscripts

1
2
3 **Title: Imported Malaria: Key Messages in an Era of Elimination.**
4

5
6 **Abstract**
7

8 Despite concerted efforts to eliminate malaria, it remains a major global cause of morbidity and
9 mortality with over 200 million annual cases. Significant gains have been made, with the annual
10 global malaria incidence and mortality halving over the past twenty years, using tools such as
11 long-lasting insecticide-treated bednets and artemisinin-based therapies. Malaria is also a
12 significant cause of life-threatening imported infection in the UK. It is vital for front line clinical
13 staff involved in the assessment of acutely ill patients to be aware of the need for early
14 diagnostic testing, malaria epidemiology, markers of severe infection, and developments in
15 antimalarial treatments to optimize patient management. The difference between a good and
16 poor outcome is early diagnosis and treatment. Many of the challenges faced in the quest for
17 global eradication, such as availability of appropriate diagnostic tests, and drug and insecticide
18 resistance could also have future implications for imported malaria.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Key points**
41

- 42 1. Malaria must be considered in all patients with history of fever who visited malaria
43 endemic areas within the preceding year.
- 44 2. Blood film microscopy remains the gold standard for malaria diagnosis, with rapid
45 diagnostic tests serving as useful adjuncts.
- 46 3. Intravenous artesunate is the drug of choice for patients with severe falciparum malaria;
47 oral artemisinin-based combinations are recommended for uncomplicated malaria.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3
- 4 4. Malaria elimination is being pursued in several countries with the eventual aim of global
- 5 eradication, but despite successes it remains common especially in Africa.
- 6
- 7
- 8 5. Malaria science is advancing rapidly including a falciparum malaria vaccine and a new
- 9 drug for vivax malaria relapse being licensed in the last two years.
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17

18 **Introduction**

19
20 Malaria, caused by *Plasmodium* parasites and transmitted by anopheline mosquitoes, remains a
21 major cause of global morbidity and mortality with an estimated 216 million cases in 2016 and
22 445 000 deaths.¹ Recent efforts to control and eventually eliminate malaria have reduced the
23 disease burden in several countries, but it remains an important cause of imported infection in
24 the UK, with 1792 cases reported in 2017, causing 6 deaths. *Plasmodium falciparum* accounts
25 for 81% of UK infections.² During the 20th century malaria was eliminated from many temperate
26 regions, including England, but remains endemic to 91 countries worldwide.¹ Several species of
27 parasite cause human malaria (*P. falciparum*, *P. vivax*, *P. ovale curtisi*, *P. ovale wallikeri*, and *P.*
28 *malariae*), with the zoonotic *P. knowlesi* an important human pathogen in parts of southeast
29 Asia.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Key Points for UK Clinicians**

48
49
50 Updated UK malaria treatment guidelines were published in 2016.³ Here we highlight key
51 messages and recent changes.
52
53
54
55
56
57
58
59
60

Clinical presentation.

The incubation period and clinical presentation of malaria are highly variable and non-specific, and missed or late diagnosis is life-threatening. Symptoms begin during the blood stage of infection (Figure 1). Malaria should be considered in any patient presenting with fever or history of fever up to 1 year after returning from the tropics, or sometimes longer especially if *P. vivax* infection is a possibility. Common symptoms of uncomplicated malaria include fevers, chills, muscle and joint aches, headache. The key to diagnosis is prompt laboratory malaria testing. It is not possible to diagnose malaria based on clinical features alone. Severe malaria has a clearly defined set of clinical and laboratory criteria which must be systematically considered (Table 1); if patients have any of these they will need parenteral treatment. Elderly patients, and those who are pregnant are at particular risk of complications from malaria.⁴

Diagnosis.

Examination of blood films remains the gold standard for malaria diagnosis. Microscopy confirms or excludes malaria, identifies malaria species, and determines the density of parasitaemia. Rapid diagnostic tests (RDTs) are an additional investigation, and detect the presence of malaria antigens in a “dipstick” format.⁵ RDTs are a useful adjunct, but not a replacement for blood film microscopy. Once malaria is diagnosed treatment should start without delay.

1
2
3 Malaria is a notifiable disease in the UK. Blood films should be sent for confirmation to the
4
5 Malaria Reference Laboratory (MRL) in England and Wales, and The Scottish Parasite and
6
7 Diagnostic Reference Laboratory in Scotland.
8
9

13 **Artemisinin**

14
15 Artemisinin derivative drugs are central to the management of malaria.⁶ Parenteral artesunate
16
17 should be first line treatment in all patients diagnosed with severe malaria including children
18
19 and all trimesters of pregnancy. Artesunate has been shown to reduce mortality compared to
20
21 quinine in two large trials (SEAQUAMAT in South East Asia,⁷ and AQUAMAT in Africa).⁸
22
23

24
25 Artesunate does not hold a UK license, but is available in many UK infectious diseases units and
26
27 can be urgently supplied from specialist tropical medicine centres in London and Liverpool
28
29 (contact details below). Malaria is life-threatening, and can progress rapidly, so if artesunate is
30
31 not immediately available, treatment of severe malaria with IV quinine should not be delayed
32
33 whilst artesunate is being obtained. If you are not experienced in managing severe malaria we
34
35 recommend getting advice from a specialist centre for the complications including cerebral
36
37 malaria, acute lung injury and renal failure, but in all situations prompt administration of high
38
39 dose intravenous artesunate (or quinine if not available) is the most important intervention.
40
41
42
43
44
45
46

47 For non-severe malaria, oral artemisinin combination therapies (ACTs) are the treatment of
48
49 choice. Two ACTs are licensed for use in the UK, artemether-lumefantrine (Riamet®) and
50
51 dihydroartemesinin-piperaquine (Eurartesim®); the former more commonly stocked by UK
52
53 pharmacies.
54
55
56
57
58
59
60

Non-Falciparum Malaria

Non-falciparum malaria (*vivax*, *ovale*, *malariae*) can be treated with ACT or, if ACT is unavailable, with chloroquine. These infections are usually treated with oral drugs as outpatients, but if signs of severity or vomiting are present, admission for parental treatment is appropriate. Deaths do occur, especially in the elderly.⁹ In *P. vivax* and *P. ovale* spp. malaria it is important to ensure eradication of hypnozoites in the liver to prevent relapse of infection.

Primaquine is the current hypnozoitocidal drug, with 14 days of follow on treatment after the schizonticide recommended to required prevent relapse. Patients may fail to complete the full 14-day primaquine course. Primaquine treatment is complicated by haemolysis risk in patients with G6PD deficiency which can be severe, and G6PD screening is required before primaquine can be given. A new drug, tafenoquine, has been given a license for *vivax* relapse by the FDA in 2018. Tafenoquine is a single dose radical cure but has the same risks with G6PD deficiency as primaquine, so may increase adherence but does not reduce the safety risk.

The Global Outlook: new directions

Malaria Eradication, and its implications for imported infection.

Significant progress towards local elimination of malaria has been made over the past 20 years with the aim of eventual global eradication. Whilst control has improved substantially in some countries the slowest progress is in some of the highest transmission settings in sub-Saharan Africa and significant numbers of imported cases can be expected from Africa for the foreseeable future.¹

1
2
3 The primary target for malaria elimination is *P. falciparum*. As transmission falls within a
4
5 population there may be an overall decrease in the prevalence of partial immunity to
6
7 falciparum malaria, and a consequent increase in the risk of severe disease in individuals who
8
9 are infected. Assuming adults from Africa with imported malaria are semi-immune is
10
11 increasingly unlikely to be a safe clinical approach. Hypnozoite-mediated relapse of vivax
12
13 malaria is difficult to prevent, so an epidemiological shift towards a higher proportion of *P.*
14
15 *vivax* infections can occur as *P. falciparum* infections become less prevalent. This is already
16
17 apparent in parts of Asia and Latin America.
18
19
20
21
22
23
24

25 *Vector Control*

26
27 The biggest impact on malaria incidence in high transmission settings has probably come from
28
29 Long-Lasting Insecticide treated Nets (LLINs). The widespread distribution and increasing
30
31 acceptance of LLINs has had a dramatic influence on malaria morbidity and mortality, but
32
33 increasingly prevalent pyrethroid resistance in *Anopheles* mosquitoes is a potential threat to
34
35 continued success which is difficult to combat.¹⁰ There is a risk that protection of travellers
36
37 under LLINs will decrease.
38
39
40
41
42
43
44

45 *Drug Resistance*

46
47 Like other micro-organisms, *Plasmodium* is capable of developing resistance under selective
48
49 drug pressure. In the 1990s, the global spread of resistance to chloroquine and sulfadoxine-
50
51 pyramethamine lead to increased morbidity and mortality, particularly in African children.¹¹ The
52
53 emergence and spread of artemisinin resistance in South-East Asia over the past decade is now
54
55
56
57
58
59
60

1
2
3 a major cause for concern and a serious potential threat to global health, given the reliance on
4
5 artesunate for severe disease, and ACTs for non-severe malaria. Artemisinin resistance causes
6
7 delayed parasite clearance and post-treatment gametocytaemia, suggesting increased potential
8
9 for onward transmission.¹² At present, proven artemisinin resistance is confined to Asia. The
10
11 spread of artemisinin resistance into areas of higher endemicity, particularly certain areas in
12
13 sub-Saharan Africa, would represent a major setback for malaria control. In the UK, there is
14
15 limited but emerging evidence for treatment failure of non-severe imported malaria with
16
17 artemether-lumefantrine.¹³ We need to remain vigilant for signs of reduced artemether-
18
19 lumefantrine efficacy among imported cases of malaria. A shift to the more widespread use of
20
21 alternative ACTs such as dihydroartemisinin-piperaquine in the future may be required.
22
23
24
25
26
27
28
29

30 **Diagnostic Challenges in Elimination and Imported Malaria.**

31
32 Case finding is key both to a successful elimination programme and to diagnosing malaria in
33
34 low-endemic settings including imported malaria to non-endemic countries. Specialist
35
36 parasitology laboratories have a very high sensitivity for clinical malaria, but this is not always
37
38 shared by routine laboratories. We need better tests for identifying low parasite density
39
40 infections (common in imported malaria), asymptomatic patients at risk of relapse with *P. vivax*
41
42 and *P. ovale* spp., methods to identify pockets of high transmission where overall malaria
43
44 incidence is falling, and means to identify the last few cases at the end of an elimination
45
46 campaign. These challenges would all benefit from more sensitive point of care tests.¹⁴ A
47
48 concern identified over recent years is the emergence of strains of *P. falciparum* in the
49
50 Americas and Africa with deletions in the PfHRP2 gene leading to false negative RDTs.¹⁵ It is not
51
52
53
54
55
56
57
58
59
60

1
2
3 yet clear how widespread this is, but in malaria imported from some countries the proportion
4
5 may be high enough to limit the usefulness of HRP2-only RDTs if used as the only diagnostic
6
7 test. This is a persuasive reason to maintain malaria microscopy.
8
9

10 11 12 13 **Vaccine Development**

14
15 An effective malaria vaccine would be transformational but has proved difficult to achieve.
16
17 Many immunogens have been tried including whole irradiated parasites, viral vectors encoding
18
19 malaria peptides, and protein subunits.¹⁶ The protein-in-adjuvant RTS,S/AS01 vaccine is the
20
21 most advanced candidate, has been licensed for use in children in endemic countries and has
22
23 been shown to elicit modest and relatively short-lived efficacy in phase 3 evaluation.¹⁷ A more
24
25 substantial efficacy was observed in older children (36.3% in 5-17 month olds). Whilst it may
26
27 play an important role in control in some endemic settings, the current vaccine is unlikely to
28
29 shift the epidemiology in most countries of relevance to travellers, or to be effective as a
30
31 travellers vaccine against malaria.
32
33
34
35
36
37
38
39

40 **Conclusions**

41
42 Malaria remains an important cause of life-threatening imported infection in the UK; prompt
43
44 diagnosis with microscopy and treatment are essential. Recent scientific developments
45
46 including new drugs, diagnostics, a vaccine and initiatives for local elimination of malaria are
47
48 important for control but will have limited impact on imported malaria in the next few years.
49
50
51
52
53

54 Useful contacts
55
56
57
58
59
60

1
2
3 Malaria Reference Laboratory [https://www.gov.uk/government/publications/malaria-](https://www.gov.uk/government/publications/malaria-reference-laboratory-mrl-user-handbook)
4
5
6 reference-laboratory- mrl-user-handbook.

7
8 Scottish Parasite and Diagnostic Reference Laboratory

9
10 [http://www.nhsggc.org.uk/about-us/professional-support- sites/scottish-microbiology-](http://www.nhsggc.org.uk/about-us/professional-support-sites/scottish-microbiology-reference-laboratories/scottish-parasite-diagnostic-reference-laboratory/)
11
12
13 reference-laboratories/ scottish-parasite-diagnostic-reference-laboratory/

14
15 Hospital for Tropical Diseases, UCH, London. 020 3456 7890.

16
17
18 Tropical and Infectious Disease Unit, Royal Liverpool University Hospital. 0151 706 2000.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

References

- 1 WHO. World Malaria Report 2017. (2018).
- 2 Malaria imported into the United Kingdom: 2017. (Public Health England, 2018).
- 3 Laloo, D. G. *et al.* UK malaria treatment guidelines 2016. *The Journal of infection* **72**, 635-649, doi:10.1016/j.jinf.2016.02.001 (2016).
- 4 Checkley, A. M. *et al.* Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. *BMJ* **344**, e2116, doi:10.1136/bmj.e2116 (2012).
- 5 Chiodini, P. L. Malaria diagnostics: now and the future. *Parasitology* **141**, 1873-1879, doi:10.1017/S0031182014001371 (2014).
- 6 Ashley, E. A., Pyae Phyo, A. & Woodrow, C. J. Malaria. *Lancet* **391**, 1608-1621, doi:10.1016/S0140-6736(18)30324-6 (2018).
- 7 Dondorp, A. *et al.* Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet* **366**, 717-725, doi:10.1016/S0140-6736(05)67176-0 (2005).
- 8 Dondorp, A. M. *et al.* Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* **376**, 1647-1657, doi:10.1016/S0140-6736(10)61924-1 (2010).
- 9 Broderick, C. *et al.* Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study. *BMJ* **350**, h1703, doi:10.1136/bmj.h1703 (2015).
- 10 Protopopoff, N. *et al.* Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. *Lancet* **391**, 1577-1588, doi:10.1016/S0140-6736(18)30427-6 (2018).
- 11 Snow, R. W., Trape, J. F. & Marsh, K. The past, present and future of childhood malaria mortality in Africa. *Trends in parasitology* **17**, 593-597 (2001).
- 12 Ashley, E. A. *et al.* Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* **371**, 411-423, doi:10.1056/NEJMoa1314981 (2014).
- 13 Sutherland, C. J. *et al.* pfk13-Independent Treatment Failure in Four Imported Cases of *Plasmodium falciparum* Malaria Treated with Artemether-Lumefantrine in the United Kingdom. *Antimicrobial agents and chemotherapy* **61**, doi:10.1128/AAC.02382-16 (2017).
- 14 Tanner, M. *et al.* Malaria eradication and elimination: views on how to translate a vision into reality. *BMC medicine* **13**, 167, doi:10.1186/s12916-015-0384-6 (2015).
- 15 Gamboa, D. *et al.* A large proportion of *P. falciparum* isolates in the Amazon region of Peru lack pfrp2 and pfrp3: implications for malaria rapid diagnostic tests. *PLoS One* **5**, e8091, doi:10.1371/journal.pone.0008091 (2010).
- 16 Ouattara, A. & Laurens, M. B. Vaccines against malaria. *Clin Infect Dis* **60**, 930-936, doi:10.1093/cid/ciu954 (2015).
- 17 Rts, S. C. T. P. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet*, doi:10.1016/S0140-6736(15)60721-8 (2015).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

18 WHO. World Malaria Report 2016. (WHO, 2016).

For Review Only

Major features of severe or complicated falciparum malaria in adults.
Cerebral involvement: Impaired consciousness, seizures, neurological signs
Pulmonary oedema, acute respiratory distress syndrome (ARDS)
Renal impairment (oliguria <0.4 ml/kg bodyweight per hour or creatinine >265 mmol/l)
Metabolic & Lactic Acidosis (pH < 7.3).
Hypoglycemia (<2.2 mmol/l).
Anaemia (Haemoglobin ≤80 g/L).
Spontaneous bleeding/disseminated intravascular coagulation.
Hypovolaemia/Shock (BP < 90/60 mmHg).
Haemoglobinuria (without G6PD deficiency).
Parasitaemia >10% (In the UK a parasitaemia of >2% or ≤2% with schizonts present indicates potentially severe malaria, and is an indication for parenteral treatment)
Pregnancy: Malaria can be more severe in pregnancy. Early consultation with a specialist unit should be made, and parenteral therapy should be considered.

Table 1: Major clinical and laboratory features of severe malaria

Figure 1 legend:

The malaria parasite life cycle in humans begins when a malaria-infected female Anopheles mosquito takes a blood meal (1). Sporozoites in the mosquito salivary glands are inoculated into the human host. The sporozoites travel via the blood to the liver in a matter of minutes, where they infect hepatocytes and mature into schizonts over days to weeks (2). This stage is asymptomatic. In *P. vivax* and *P. ovale* infection, a dormant stage (hypnozoites) can persist in the liver and cause relapses by invading the bloodstream weeks, or even years later. Mature hepatic schizonts rupture and release merozoites which infect erythrocytes in the peripheral blood stream. This marks the start of the blood stage of infection, during which the clinical manifestations of malaria occur (3). The parasites mature within the erythrocytes into ring stage trophozoites and then into schizonts, which rupture releasing more merozoites and allowing the blood stage cycle to begin again. Some parasites differentiate into sexual erythrocytic stages (gametocytes) which are ingested by an Anopheles mosquito during a blood meal (4). The gametocytes mature in the mosquito through the sporogonic cycle, ultimately resulting in infective sporozoites in the salivary glands in preparation for inoculation into a new human host.

SAQs

1. Which of the following species of malaria is associated with the majority of deaths, both globally, and in the UK?

- a. *P. ovale*
- b. *P. malariae*
- c. *P. vivax*,
- d. *P. falciparum*
- e. *P. knowlesi*

Correct answer d.

P. falciparum accounts for nearly all malaria deaths worldwide. Severe disease and death can occur with other species, but is rare.

2. A 34 year old male patient is brought to A&E having returned from visiting friends and relatives in Burkina Faso 5 days previously. He is drowsy with a GCS of 10. He has a temperature of 38.9°C, blood pressure of 100/60, respiratory rate of 26. Bloods show an Hb of 109 g/dL, Plts 93, WBC 2.8, Creatinine 183 µmol/l, PaO₂(Air) 9.5kpa, pH 7.25. Blood film shows early and late trophozoites of *P. falciparum* with 12% of RBCs parasitised. What antimalarial should he receive?

- a. IV Quinine
- b. Dihydroartemisinin-piperaquine (Euartesim®)
- c. Tafenoquine
- d. IV Artesunate

- 1
2
3 e. Atovaquone-proguanil (Malarone®)
4
5

6 **Correct answer d.**
7


8 This patient has severe malaria and should receive IV artesunate. IV Quinine should be used if
9
10 IV artesunate is not available.
11
12
13
14

15 3. Which of the following is a potential sign of severe malaria in adults?
16

- 17 a. Platelets below $90 \times 10^9/L$
18
19 b. Temperature $>38.7^\circ C$
20
21 c. Haemoglobin 10.1 g/Dl
22
23 d. Parasite count 1.3% of red cells parasitized.
24
25 e. Glasgow coma scale 10.
26
27
28
29

30 **Correct answer e.**
31

32 Please refer to Table 1 for an outline of the features of severe malaria.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



The malaria parasite life cycle in humans begins when a malaria-infected female Anopheles mosquito takes a blood meal (1). Sporozoites in the mosquito salivary glands are inoculated into the human host. The sporozoites travel via the blood to the liver in a matter of minutes, where they infect hepatocytes and mature into schizonts over days to weeks (2). This stage is asymptomatic. In *P. vivax* and *P. ovale* infection, a dormant stage (hypnozoites) can persist in the liver and cause relapses by invading the bloodstream weeks, or even years later. Mature hepatic schizonts rupture and release merozoites which infect erythrocytes in the peripheral blood stream. This marks the start of the blood stage of infection, during which the clinical manifestations of malaria occur (3). The parasites mature within the erythrocytes into ring stage trophozoites and then into schizonts, which rupture releasing more merozoites and allowing the blood stage cycle to begin again. Some parasites differentiate into sexual erythrocytic stages (gametocytes) which are ingested by an Anopheles mosquito during a blood meal (4). The gametocytes mature in the mosquito through the sporogonic cycle, ultimately resulting in infective sporozoites in the salivary glands in preparation for inoculation into a new human host.